Jane Street
IBIO icon

Jane Street’s iBio IBIO Stock Holding History

Jane Street’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-160
Closed -$44K – 10612
2021
Q4 		$44K Sell
160
-59
-27% -$22.5K ﹤0.01% 9579
2021
Q3 		$116K Sell
219
-92
-30% -$57.3K ﹤0.01% 9210
2021
Q2 		$235K Buy
311
+157
+102% +$115K ﹤0.01% 8571
2021
Q1 		$119K Buy
+154
New +$134K ﹤0.01% 8568

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Jane Street's IBIO Position: Q1 2026 in Review

Jane Street sold out of iBio (IBIO) in Q1 2026, closing a stake of 105,700 shares — an estimated $204K sold.

Jane Street first reported a position in IBIO in Q1 2020 and held it in 11 quarters. The position peaked at $718K in Q2 2020. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Jane Street reported no remaining iBio position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 105,700 iBio shares in Q1 2026, an estimated $204K.
  • Jane Street first reported a position in iBio in Q1 2020 and held it in 11 quarters.
  • Jane Street's iBio position peaked at $718K in Q2 2020.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.